Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Mounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...